The regulatory green light follows a comprehensive review of five-year clinical data confirming the safety and efficacy of the implant. Unlike traditional anti-reflux surgeries that rely on wrapping or encircling the esophagus—a method often linked to swallowing difficulties and gas bloating—RefluxStop restores the natural anatomy of the gastroesophageal junction without applying external pressure.

CEO Peter Forsell noted that the company is entering the U.S. landscape with a mature foundation, leveraging experience from nearly 1,800 patient cases and over 60 European centers of excellence. While the initial rollout will be limited to select surgical centers, the company plans a disciplined scale-up centered on physician training and site activation. This approval shifts Implantica’s primary focus from clinical development to commercial execution in a sector where standard-of-care treatments have long remained unchanged.